527 results on '"Mehta‐Shah, Neha"'
Search Results
2. Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
3. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
4. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
5. The Post-transplant Lymphoproliferative Disorders—Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and Protocol
6. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome
7. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
8. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
9. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma
10. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas
11. A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas
12. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
13. Peripheral T-cell lymphoma: are all patients high risk?
14. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
15. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
16. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL
17. Management of Peripheral T-cell Lymphomas and the Role of Transplant
18. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
19. Prognosis and risk stratification of peripheral T-cell lymphomas
20. Enteropathy-Associated T-Cell Lymphomas
21. Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma.
22. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
23. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma
24. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
25. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
26. Failing Forward in Peripheral T-Cell Lymphoma
27. Scarring alopecia developing after mogamulizumab-associated rash
28. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
29. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma
30. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma
31. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma
32. Peripheral T-cell lymphoma: Are all patients high-risk?
33. Gamma delta lymphoma: a pictorial review of F-18 fluorodeoxyglucose PET/CT findings and a brief review of the literature
34. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
35. Optimizing Frontline Treatment for PTCL
36. TCL-495 Evaluation of Breast Implant-Associated Anaplastic Large Cell Lymphoma With Whole Exome and Genome Sequencing
37. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
38. EXABS-185-TCL The Next Rational Therapeutic Regimen in Newly Diagnosed PTCL
39. How I treat breast implant–associated anaplastic large cell lymphoma
40. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients
41. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
42. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma
43. Supplementary Figure 5 from Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma
44. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
45. SOHO State of the Art Updates and Next Questions | Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas
46. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma
47. Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
48. TCL-306 Quality of Life in Patients With Cutaneous T-Cell Lymphoma: Validation of a Novel Quality of Life Instrument
49. TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)
50. POSTER: TCL-306 Quality of Life in Patients With Cutaneous T-Cell Lymphoma: Validation of a Novel Quality of Life Instrument
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.